Selective BRAF inhibitors (dabrafenib, vemurafenib, encorafenib) and MEK inhibitors (trametinib, cobimetinib, binimetinib) have demonstrated robust clinical activity, particularly in melanoma, non-small cell lung carcinoma (NSCLC), and colorectal carcinoma harboring MAPK pathway alterations [54]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.